TissGeneSummary for EID3 |
Gene summary |
Basic gene information | Gene symbol | EID3 |
Gene name | EP300 interacting inhibitor of differentiation 3 | |
Synonyms | NS4EB|NSE4B|NSMCE4B | |
Cytomap | UCSC genome browser: 12q23.3 | |
Type of gene | protein-coding | |
RefGenes | NM_001008394.2, | |
Description | E1A-like inhibitor of differentiation 3EID-1-like inhibitor of differentiation 3EID-3EP300-interacting inhibitor of differentiation 3non-SMC element 4 homolog Bnon-structural maintenance of chromosomes element 4 homolog B | |
Modification date | 20141207 | |
dbXrefs | MIM : 612986 | |
HGNC : HGNC | ||
Ensembl : ENSG00000255150 | ||
HPRD : 17415 | ||
Vega : OTTHUMG00000165912 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_EID3 | |
BioGPS: 493861 | ||
Pathway | NCI Pathway Interaction Database: EID3 | |
KEGG: EID3 | ||
REACTOME: EID3 | ||
Pathway Commons: EID3 | ||
Context | iHOP: EID3 | |
ligand binding site mutation search in PubMed: EID3 | ||
UCL Cancer Institute: EID3 | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | HPA,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
Reference showing the relevant tissue of EID3 | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for EID3 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
PRAD | -0.692435787 | 0.481233444 | -1.173669231 | 6.16E-14 | 4.92E-12 |
COAD | -2.167976172 | -0.988156941 | -1.179819231 | 1.66E-08 | 1.39E-07 |
BLCA | -0.934067467 | 0.152164112 | -1.086231579 | 0.00772 | 0.036765054 |
Top |
TissGene-miRNA for EID3 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for EID3 |
TissGeneSNV for EID3 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.N250T | UCEC | 1 |
p.R193S | PAAD | 1 |
p.A32T | PAAD | 1 |
p.S109* | ESCA | 1 |
p.N130H | READ | 1 |
p.E166K | BRCA | 1 |
p.R179H | STAD | 1 |
p.A90T | UCEC | 1 |
p.R179S | LUAD | 1 |
p.E102* | UCEC | 1 |
p.E284Q | BLCA | 1 |
p.D89N | UCEC | 1 |
p.S61L | BLCA | 1 |
p.R185Q | LUAD | 1 |
p.I307M | HNSC | 1 |
p.R233Q | UCEC | 1 |
p.R38H | UCEC | 1 |
p.S109X | ESCA | 1 |
p.E257D | UCEC | 1 |
p.E68* | LUAD | 1 |
p.V306A | UCEC | 1 |
p.N130I | STAD | 1 |
p.M132I | LUAD | 1 |
p.R38H | COAD | 1 |
p.R8S | STAD | 1 |
p.T167I | STAD | 1 |
p.G294E | READ | 1 |
p.I328N | TGCT | 1 |
p.D89N | STAD | 1 |
p.P281R | CESC | 1 |
p.A158V | SKCM | 1 |
p.H169Q | KIRP | 1 |
Top |
TissGeneCNV for EID3 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for EID3 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Top |
TissGeneNet for EID3 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for EID3 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for EID3 |
TissGeneDrug for EID3 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for EID3 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |